PT  - JOURNAL ARTICLE
AU  - Jean-Dominique Gallezot
AU  - Nabeel Nabulsi
AU  - Shannan Henry
AU  - Richard Pracitto
AU  - Beata Planeta
AU  - Jim Ropchan
AU  - Shu-Fei Lin
AU  - David Labaree
AU  - Michael Kapinos
AU  - Anupama Shirali
AU  - Teresa Lara-Jaime
AU  - Hong Gao
AU  - David Matuskey
AU  - Mark Walzer
AU  - Gerard J. Marek
AU  - Susan Bellaire
AU  - Nancy Yuan
AU  - Richard E. Carson
AU  - Yiyun Huang
TI  - Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer <sup>11</sup>C-AS2471907 in Human Brain
AID  - 10.2967/jnumed.118.219766
DP  - 2019 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1140--1146
VI  - 60
IP  - 8
4099  - http://jnm.snmjournals.org/content/60/8/1140.short
4100  - http://jnm.snmjournals.org/content/60/8/1140.full
SO  - J Nucl Med2019 Aug 01; 60
AB  - The 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme converts cortisone to cortisol and participates in the regulation of glucocorticoid levels in tissues. 11β-HSD1 is expressed in the liver, kidney, adipose tissue, placenta, and brain. 11β-HSD1 is a target for treatment of depression, anxiety, posttraumatic stress disorder, and also against age-related cognitive function and memory loss. In this study, we evaluated the radiotracer 11C-AS2471907 (3-(2-chlorophenyl)-4-(methyl-11C)-5-[2-[2,4,6-trifluorophenoxy]propan-2-yl]-4H-1,2,4-triazole) to image 11β-HSD1 availability in the human brain with PET. Methods: Fifteen subjects were included in the study. All subjects underwent one 2-h scan after a bolus administration of 11C-AS2471907. Two subjects underwent an additional scan after blockade with the selective and high-affinity 11β-HSD1 inhibitor ASP3662 to evaluate 11C-AS2471907 nondisplaceable distribution volume. Five subjects also underwent an additional scan to evaluate the within-day test–retest variability of 11C-AS2471907 volumes of distribution (VT). Results: 11C-AS2471907 time–activity curves were best fitted by the 2-tissue-compartment (2TC) model. 11C-AS2471907 exhibited a regionally varying pattern of uptake throughout the brain. The VT of 11C-AS2471907 ranged from 3.7 ± 1.5 mL/cm3 in the caudate nucleus to 14.5 ± 5.3 mL/cm3 in the occipital cortex, with intermediate values in the amygdala, white matter, cingulum, insula, frontal cortex, putamen, temporal and parietal cortices, cerebellum, and thalamus (from lowest to highest VT). From the blocking scans, nondisplaceable distribution volume was determined to be 0.16 ± 0.04 mL/cm3 for 11C-AS2471907. Thus, nearly all uptake was specific and the binding potential ranged from 22 in the caudate to 90 in the occipital cortex. Test–retest variability of 2TC VT values was less than 10% in most large cortical regions (14% in parietal cortex) and ranged from 14% (cerebellum) to 51% (amygdala) in other regions. The intraclass correlation coefficient of 2TC VT values ranged from 0.55 in the white matter to 0.98 in the cerebellum. Conclusion: 11C-AS2471907 has a high fraction of specific binding in vivo in humans and reasonable within-day reproducibility of binding parameters.